Abstract:
The present invention relates to the protected intermediates and the deprotected products of P6A, related to the protected pseudopeptides introducing the protected intermediateds of P6A to 3S-(2-Boc)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid and the deprotected pseudopeptides, related to the protected pseudopeptides introducing the protected intermediateds of P6A to 3S-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid benzyl ester, related to the methods for their preparation, and related to their use as the thrombolytic agents.
Abstract:
The present invention relates to the protected intermediates and the deprotected products of P6A, related to the protected pseudopeptides introducing the protected intermediateds of P6A to 3S-(2-Boc)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid and the deprotected pseudopeptides, related to the protected pseudopeptides introducing the protected intermediateds of P6A to 3S-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid benzyl ester, related to the methods for their preparation, and related to their use as the thrombolytic agents.
Abstract:
The present invention discloses a series of benzoylamino-1,3-dioxacyclane compounds, of which compounds 1-21 were prepared via transacetalisation reaction between N-benzoylaminoglycol and 1,1,3,3-tetramethoxypropane; while compounds 22-48 were prepared via stereospecific acetalisation reaction between N-benzoylamino glycol and aromatic aldehyde, and if necessary, the nitro groups were reduced and further be salified with propane diacid and L-Arg or L-Lys. These compounds possess the structural type of PKC inhibitor and positive anti-inflammatory effect, and can be applied in medical fields as PKC inhibitor for corresponding therapy.
Abstract:
The present invention relates to a new kind of heavy metal chelating agents and a preparation process and uses thereof. The said heavy metal chelating agents are expressed in &agr;-[D(+)glucose-1-yl-amino]-&bgr;3-mercapto-(S)-propanoic acid (abbreviated to NGP,I) and/or N,N′-di[D(+)glucose-1-yl]-L-cystine (abbreviated to NGCD,II). In the process of preparation, glucose and cysteine are reacted with a base, with a reducing agent, and the obtained products are acidified to give NGP,I, which can be used in and/or as drugs, health foods and food additives for accelerating the excretion of heavy metals including Pb, Cd, Hg, Al, Sb, As, etc. The structural feature of the compounds of the present invention is that they contain glucose and cysteirie in their molecules. Compared with the heavy metal-excreting drugs of prior art, the compounds of the present invention have four advantages, namely suitability for oral administration, high ability to accelerate the excretion of heavy metals, high selectivity and less toxicity.